Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13037120 | 0.86 | MEN1 (0.39) | MEN1KMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL13037121 | 0.86 | MEN1 (0.39) | MEN1KMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL2603326 | 0.86 | MEN1 (0.39) | MEN1KMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL24899450 | 0.85 | HRH3 (0.41) | MEN1KMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL23785285 | 0.85 | HRH3 (0.41) | MEN1KMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL23785290 | 0.85 | HRH3 (0.41) | MEN1KMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL20122528 | 0.82 | L3MBTL3 (0.31) | — | |
| SCHEMBL10284012 | 0.80 | SIGMAR1 (0.41) | MEN1KMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL12250827 | 0.80 | MEN1 (0.40) | MEN1KMT2AALDH1A1POLBCYP3A4 | |
| SCHEMBL1083799 | 0.80 | MEN1 (0.40) | MEN1KMT2AALDH1A1POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | MCL1, BCL9, BCL9L | MEN1 269/4885KMT2A 891/4885ALDH1A1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.